Načítá se...
CAR T‐Cell Therapy Shows Durable Responses in Indolent NHL
In an update from the ongoing phase II ZUMA‐5 trial, axicabtagene ciloleucel showed a high response rate and durable clinical benefit in patients with relapsed/refractory indolent non‐Hodgkin lymphoma, including follicular lymphoma and marginal zone lymphoma.
Uloženo v:
| Vydáno v: | Oncologist |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley & Sons, Inc.
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7330923/ https://ncbi.nlm.nih.gov/pubmed/32588925 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0559 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|